AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$22.93
arrow_downward
-1.08%(-0.25) 1D
$22.93
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 8, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMPH...
Open
$22.82
High
$23.14
Low
$22.30
Mkt. cap
975.39M
Avg. vol.
434.51K
Volume
460.02K
P/E ratio
13.41
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.92
Shares outstanding
42.54M
No. of employees
2K
Open
$22.82
High
$23.14
Low
$22.30
Mkt. cap
975.39M
Avg. vol.
434.51K
Volume
460.02K
P/E ratio
13.41
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.92
Shares outstanding
42.54M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
6 hours ago
AMPH: Branded and complex generics, led by BAQSIMI, will drive growth and margin expansion through 2027
Investing.com
·
7 hours ago
Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorPharmaceutical industry
Websiteamphastar.com